Larimar Therapeutics (STU:ZA71) ROE % Adjusted to Book Value : -44.30% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics ROE % Adjusted to Book Value?

Larimar Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -64.23%. Larimar Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 1.45. Larimar Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -44.30%.

Larimar Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Larimar Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics ROE % Adjusted to Book Value Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-28.95

-24.23

-26.98

-15.78

-44.42

Larimar Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-24.65	-18.96	-17.95	-14.53	-44.30

Competitive Comparison of Larimar Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Larimar Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Larimar Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Larimar Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Larimar Therapeutics ROE % Adjusted to Book Value Calculation

Larimar Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-64.41%	/	1.45
	=	-44.42%

Larimar Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-64.23%	/	1.45
	=	-44.30%

Larimar Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

LRMR:USA

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines